Xenon Pharmaceuticals Inc. (XENE) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company's platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.
Analyst Upgrade/Downgrade Update Brokerage firm: Stifel Change: Coverage Initiated Previous Rating: N/A Current Rating: Buy Previous Price Target: N/A Current Price Target: $18
Xenon Pharmaceuticals Inc. will discontinue development of its acne drug XEN801, intended for moderate-to-severe facial acne, after it failed a Phase 2 clinical study, the Burnaby, British Columbia-based company has announced. No Better Than Placebo In the mid-stage assessment, XEN801 failed to demonstrate any statistically significant difference compared to a vehicle placebo. A placebo is a substance that has no therapeutic effect, and is used as a control in testing new drugs. A vehicle placebo is equivalent to the active drug, minus the active
